Sector • Healthcare Industry • In Vitro & In Vivo Diagnostic Substances |
Industry • In Vitro & In Vivo Diagnostic Substances |
Sector • Healthcare |
A modest 3.152%, rise in revenue at the company in the financial period ending August 31 2022
company announced first quarter of 2023 operating profit of $6.062 million
Published Oct 01 2022
CSIMarket Team / CSIMarket.com
In the previous quarter NEOG realized Revenue of $140.09 million and bottom line of $0.14 per share.
Net earnings of $5.209 million in the first quarter of 2023 earnings season fell by -69.5 % from $17.077 million in the corresponding period a year before. Neogen Corporation shifted it's focus on improving sales in the first quarter of 2023 earnings season, as a result net margin eased to 3.94%.
Operating earnings, fell -72.12% to $6.062 million, squeezing Neogen Corporation's operating margin to 4.58%, from 16.95% in the first quarter of 2022.
Neogen Corporation is expected to report next financial recent numbers on July 26, 2023.
Other NEOG's news
Neogen Reinvents Canine Parasite Protection with Provecta Pro Flea & Tick Collar for Dogs
Neogen Corporation Achieves Remarkable 72.256% Revenue Surge Throughout Q1-Q2 2023
Earnings lifted by $10.45 million tax benefit
Peculiar conduct by NEOG amid the financial period closing Nov 30 2022
A modest 3.152%, rise in revenue at the company in the financial period ending August 31 2022
Other NEOG's news
Neogen Reinvents Canine Parasite Protection with Provecta Pro Flea & Tick Collar for Dogs
Neogen Corporation Achieves Remarkable 72.256% Revenue Surge Throughout Q1-Q2 2023
Earnings lifted by $10.45 million tax benefit
Peculiar conduct by NEOG amid the financial period closing Nov 30 2022
A modest 3.152%, rise in revenue at the company in the financial period ending August 31 2022